Physician profile
John Leman Beer
NPI 1699773234
$7,853.54
in general payments reported to CMS, 2019-2025
34 companies · $2,230 in 2025
The $2,230 reported for 2025 was more than what 92% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,347 · 2022: $1,210 · 2023: $1,315 · 2024: $1,752 · 2025: $2,230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,268 · Education: $28.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,268.34 |
| Education | $28.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,156.35 | 2021-2025 | |
| Janssen Biotech, INC. | $899.91 | 2021-2025 | Tremfya, Stelara, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $891.34 | 2021-2025 | Entyvio |
| Qol Medical, LLC | $458.46 | 2021-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $450.24 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $414.79 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $287.93 | 2023-2025 | Ibsrela |
| Pfizer INC. | $234.18 | 2021-2025 | |
| Celgene Corporation | $225.31 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $213.15 | 2024-2025 | Omvoh |
| Boston Scientific Corporation | $168.77 | 2021-2024 | |
| Genzyme Corporation | $142.99 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $139.52 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $116.58 | 2022-2024 | |
| Ferring Pharmaceuticals INC. | $114.99 | 2023-2024 | Rebyota |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $97.76 | 2021 | |
| Braintree Laboratories, INC. | $96.23 | 2021-2022 | |
| Celltrion USA INC. | $95.02 | 2024-2025 | Vegzelma, Zymfentra |
| Phathom Pharmaceuticals, INC. | $92.10 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $63.39 | 2021-2022 | |
| Daiichi Sankyo INC. | $59.20 | 2021 | |
| Ironwood Pharmaceuticals, INC | $57.13 | 2021-2023 | Linzess |
| Organon LLC | $56.44 | 2024-2025 | Hadlima, Renflexis |
| Ipsen Biopharmaceuticals, INC | $54.26 | 2024-2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $48.50 | 2024-2025 | Zenpep |
| Evoke Pharma, INC. | $42.87 | 2021-2023 | Gimoti |
| Henry Schein, INC. | $41.26 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $33.48 | 2022 | |
| Medtronic, INC. | $24.48 | 2024 | Pillcam |
| Novo Nordisk INC | $19.08 | 2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $17.75 | 2021 | |
| Amgen INC. | $17.40 | 2021 | |
| Endogastric Solutions, INC | $13.44 | 2024 | Esophyx |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Beer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.